Relates to capping cost sharing for antiviral COVID-19 therapeutics
Summary
Requires insurance companies, medical expense indemnity corporations, hospital service corporations, health service corporations and medical assistance programs to provide coverage for prescribed antiviral therapeutics approved by the food and drug administration for the treatment of COVID-19 at no cost to the patient.
Bill status
in committee
1 of 4 stages cleared
Introduction
Mar 2025
Committee Review
Floor Vote
Governor
Introduced Mar 27, 2025
Last action Mar 27, 2025
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
1
Key actions
0
Committee
1
Mar 27, 2025
Committee
REFERRED TO INSURANCE
upper
1 primary · 0 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Brad Hoylman-Sigal
DDemocratic/Working Families
Ask Maddy
·
AI policy assistant
Ask Maddy about S 6925
Scope: NY
Hi! I can help you understand S 6925. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline